DDInter927 DDInter1464
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.
Picosulfuric acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digitoxin
Picosulfuric acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylcellulose
Picosulfuric acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimipramine
Picosulfuric acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Picosulfuric acid {u} may lead to a major life threatening interaction when taken with {v} Sotalol
Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Digitoxin
Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Picosulfuric acid may lead to a major life threatening interaction when taken with Sotalol